Favorable outcomes of NPM1(mut) AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance

Detalles Bibliográficos
Autores principales: Khan, I., Kaempf, A., Raghuwanshi, S., Chesnokov, M., Zhang, X., Wang, Z., Domling, A., Tyner, J. W., Camacho, C., Gartel, A. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444844/
https://www.ncbi.nlm.nih.gov/pubmed/37607920
http://dx.doi.org/10.1038/s41408-023-00898-4
_version_ 1785094043281129472
author Khan, I.
Kaempf, A.
Raghuwanshi, S.
Chesnokov, M.
Zhang, X.
Wang, Z.
Domling, A.
Tyner, J. W.
Camacho, C.
Gartel, A. L.
author_facet Khan, I.
Kaempf, A.
Raghuwanshi, S.
Chesnokov, M.
Zhang, X.
Wang, Z.
Domling, A.
Tyner, J. W.
Camacho, C.
Gartel, A. L.
author_sort Khan, I.
collection PubMed
description
format Online
Article
Text
id pubmed-10444844
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-104448442023-08-24 Favorable outcomes of NPM1(mut) AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance Khan, I. Kaempf, A. Raghuwanshi, S. Chesnokov, M. Zhang, X. Wang, Z. Domling, A. Tyner, J. W. Camacho, C. Gartel, A. L. Blood Cancer J Correspondence Nature Publishing Group UK 2023-08-22 /pmc/articles/PMC10444844/ /pubmed/37607920 http://dx.doi.org/10.1038/s41408-023-00898-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Correspondence
Khan, I.
Kaempf, A.
Raghuwanshi, S.
Chesnokov, M.
Zhang, X.
Wang, Z.
Domling, A.
Tyner, J. W.
Camacho, C.
Gartel, A. L.
Favorable outcomes of NPM1(mut) AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance
title Favorable outcomes of NPM1(mut) AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance
title_full Favorable outcomes of NPM1(mut) AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance
title_fullStr Favorable outcomes of NPM1(mut) AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance
title_full_unstemmed Favorable outcomes of NPM1(mut) AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance
title_short Favorable outcomes of NPM1(mut) AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance
title_sort favorable outcomes of npm1(mut) aml patients are due to transcriptional inactivation of foxm1, presenting a new target to overcome chemoresistance
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444844/
https://www.ncbi.nlm.nih.gov/pubmed/37607920
http://dx.doi.org/10.1038/s41408-023-00898-4
work_keys_str_mv AT khani favorableoutcomesofnpm1mutamlpatientsareduetotranscriptionalinactivationoffoxm1presentinganewtargettoovercomechemoresistance
AT kaempfa favorableoutcomesofnpm1mutamlpatientsareduetotranscriptionalinactivationoffoxm1presentinganewtargettoovercomechemoresistance
AT raghuwanshis favorableoutcomesofnpm1mutamlpatientsareduetotranscriptionalinactivationoffoxm1presentinganewtargettoovercomechemoresistance
AT chesnokovm favorableoutcomesofnpm1mutamlpatientsareduetotranscriptionalinactivationoffoxm1presentinganewtargettoovercomechemoresistance
AT zhangx favorableoutcomesofnpm1mutamlpatientsareduetotranscriptionalinactivationoffoxm1presentinganewtargettoovercomechemoresistance
AT wangz favorableoutcomesofnpm1mutamlpatientsareduetotranscriptionalinactivationoffoxm1presentinganewtargettoovercomechemoresistance
AT domlinga favorableoutcomesofnpm1mutamlpatientsareduetotranscriptionalinactivationoffoxm1presentinganewtargettoovercomechemoresistance
AT tynerjw favorableoutcomesofnpm1mutamlpatientsareduetotranscriptionalinactivationoffoxm1presentinganewtargettoovercomechemoresistance
AT camachoc favorableoutcomesofnpm1mutamlpatientsareduetotranscriptionalinactivationoffoxm1presentinganewtargettoovercomechemoresistance
AT gartelal favorableoutcomesofnpm1mutamlpatientsareduetotranscriptionalinactivationoffoxm1presentinganewtargettoovercomechemoresistance